Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. - Wikidata - awgldk - TriplyDB

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

http://www.wikidata.org/entity/Q36544641

about

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term survival in both resected and metastatic colorectal cancer: an updated systematic review and meta-analysis of 24 studies Pinin facilitated proliferation and metastasis of colorectal cancer through activating EGFR/ERK signaling pathway.CUL4A promotes proliferation and metastasis of colorectal cancer cells by regulating H3K4 trimethylation in epithelial-mesenchymal transition.Multicenter analysis of risk factors for anastomotic leakage after middle and low rectal cancer resection without diverting stoma: a retrospective study of 319 consecutive patients.Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers.Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.

P2860

Q30314225-BFCD8DF2-DA3D-4885-8DC2-265460BF72F9 Q33762117-48ED9CCD-F743-4289-885C-C499773DCAB7 Q37301846-824AA0E6-2A60-41E2-B278-F6CE07F5DF7E Q37641482-0C2785E5-E836-4A4E-B69E-3AD227BBE614 Q38647582-1670BDF1-2A6A-4650-B1B6-BA7274719DB2 Q38698206-595A58E1-F922-4C57-880B-2172F488B597 Q38802590-813BB367-5A7C-4F62-9AD5-70F422450C86 Q41044367-2BAC00B0-C013-4F41-9BCA-07509E95C3B0

P2860

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

http://www.wikidata.org/entity/Q36544641

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

@ast

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

@en

type

label

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

@ast

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

@en

prefLabel

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

@ast

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

@en

P1433

Q36544641-018ABD25-CD3A-47A9-9D50-85A504EDBCFC

P1476

Q36544641-3191BB9B-0C73-4940-8559-54CAD7DD5DDB

P2093

Q36544641-00531A23-4502-4E4E-9D39-8E3D5F436E58

Q36544641-02D22FDB-5475-4FA6-AB97-54FED0785DF2

Q36544641-136F5BDD-F538-46CE-B6D3-8683CD6BEB18

Q36544641-266D025C-FF19-484A-893C-9B2D526A1018

Q36544641-2D83B6D5-CBC1-4229-A025-2C1D5B528FAF

Q36544641-37C9B6AC-83D0-4ADB-8692-2F7908E720D6

Q36544641-3901B00D-4F74-428C-AF02-8B65804CFECA

Q36544641-3D013F0C-0EE6-44C2-B212-08CE8D2C3B45

Q36544641-3EEC1786-ACD8-40F4-8EFE-A899E7DF04B6

Q36544641-4781835A-243C-4CDC-AEBA-20547F0526E8

P2860

Q36544641-05344AFA-A651-48FB-8DE1-50AF1FC0D064

Q36544641-13405E98-B54A-43B4-9D31-F684B38423BC

Q36544641-15A60162-2916-4E32-ABA9-3680EC6384D2

Q36544641-167D3D22-CD9A-4E1A-B559-5514C390B597

Q36544641-21D79848-A4FF-4385-BE90-B1C6F1CB6DC7

Q36544641-2488B34A-0697-41BA-9D66-90577625FBF6

Q36544641-2CAB5AE2-A1BD-4576-97CA-A4F8D0C26FDF

Q36544641-30A78DF2-AFA4-4B2D-B873-1E62BDFCEDB7

Q36544641-357468DC-0D84-422F-B938-4D88AD00C508

Q36544641-471272FD-3389-4D5A-ADF1-957DCDAA72A3

P304

Q36544641-2068E7EE-F63A-4E6C-9EBB-53ABC1E8C0E5

P31

Q36544641-F8E8AF2E-7BA5-4594-A576-ED0BF6F92414

P356

Q36544641-B950C4CE-11BB-4DFE-AC07-003CD66F55AB

P407

Q36544641-AC746FA5-88EA-4D65-B808-7C8BAB6FE5D2

P433

Q36544641-78650485-7642-4F93-914D-BA83510B8232

P478

Q36544641-ECEFAB25-FE6D-435C-AFA9-25ABD1020695

P50

Q36544641-2958F816-FE92-4380-A61B-822465577127

Q36544641-38F8C4BA-F957-4163-BF53-64FBFA6D4C15

Q36544641-42CE9B92-3140-43EB-BD98-1B927A731F5F

Q36544641-57F16459-1C45-491B-A86A-C3AE74B64E68

Q36544641-65C33C12-6B4F-4AFD-99B6-AE733F8C5F1A

Q36544641-76375A97-A1A7-40E5-9D29-9201505D5837

Q36544641-7BA94EB6-82D3-4401-9D78-9181E15DA09C

Q36544641-88D810FC-28F7-4DF2-8831-6ECECD541CFB

Q36544641-98D1C863-2F33-4A77-A0D9-3079134BB828

Q36544641-B48A1472-7919-46E9-B3E6-F4265CE52C9C

P577

Q36544641-6C6569B7-6CA2-4A76-A4EF-DCCBFB0EC6F5

P5875

Q36544641-4E6457CF-22B4-4C1A-BD88-B9CA1F3877BF

P698

Q36544641-99B958CF-A472-4D61-AC60-3D33F319253A

P921

Q36544641-75BF3EBA-07DD-415F-9B08-A966DB2E39CE

P932

Q36544641-0DF770FA-7446-4611-B803-DAD2246E3313

P356

ONCOTARGET.5231

P1433

P1476

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

@en

P2093

Alice Zoccoli

http://www.w3.org/2001/XMLSchema#string

Antonio Russo

http://www.w3.org/2001/XMLSchema#string

Bruno Vincenzi

http://www.w3.org/2001/XMLSchema#string

Daniele Rossini

http://www.w3.org/2001/XMLSchema#string

Daniele Santini

http://www.w3.org/2001/XMLSchema#string

Elena Ongaro

http://www.w3.org/2001/XMLSchema#string

Emanuela Dell'Aquila

http://www.w3.org/2001/XMLSchema#string

Erica Bonazzina

http://www.w3.org/2001/XMLSchema#string

Giovanna De Maglio

http://www.w3.org/2001/XMLSchema#string

Giuseppe Aprile

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

P304

31604-31612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.5231

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Sartore-Bianchi

Francesco Pantano

Gabriella Fontanini

Fotios Loupakis

Alfredo Falcone

Chiara Cremolini

Andrea Onetti Muda

Salvatore Siena

Francesco Mannavola

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282043558

http://www.w3.org/2001/XMLSchema#string

P698

26384309

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4741627

http://www.w3.org/2001/XMLSchema#string